Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solomon J Lubinga

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
African Health Sciences|March 10, 2016
Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in UgandaBarbra Katusiime, Daniel Semakula, Solomon J Lubinga
BMC Research Notes|October 13, 2011
Pilot evaluation of the psychometric properties of a self-medication Risk Assessment Tool among elderly patients in a community settingSolomon J Lubinga, Ian Millar, Joseph B Babigumira
Value in Health Regional Issues|April 3, 2026
Healthcare Resource Utilization and Costs After Disease Progression With First-Line Systemic Therapy in Patients With Advanced Endometrial Cancer in the United StatesLaura Moore-Schiltz, Solomon J Lubinga, Joseph Tkacz
Journal of Medical Economics|September 10, 2024
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspectiveSolomon J Lubinga, Lydia Walder, Mark Burton, et al.
Plos Neglected Tropical Diseases|August 12, 2016
A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African NationsDavid Watkins, Solomon J Lubinga, Bongani Mayosi, et al.
Blood Transfusion = Trasfusione Del Sangue|November 29, 2016
Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasmaJoseph B Babigumira, Solomon J Lubinga, Emma Castro, et al.
Journal of Managed Care & Specialty Pharmacy|August 23, 2023
Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitorsDavid Stenehjem, Solomon J Lubinga, Aozhou Wu, et al.
Applied Health Economics and Health Policy|May 11, 2015
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in UgandaSolomon J Lubinga, Byamah B Mutamba, Angelo Nganizi, et al.
Plos One|November 13, 2015
Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in UgandaSolomon J Lubinga, Esther C Atukunda, George Wasswa-Ssalongo, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|August 26, 2023
Cost Effectiveness of Early Endovenous Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis in the United KingdomJoseph B Babigumira, Stephen A Black, Solomon J Lubinga, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
African Health Sciences|March 10, 2016
Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in UgandaBarbra Katusiime, Daniel Semakula, Solomon J Lubinga
BMC Research Notes|October 13, 2011
Pilot evaluation of the psychometric properties of a self-medication Risk Assessment Tool among elderly patients in a community settingSolomon J Lubinga, Ian Millar, Joseph B Babigumira
Value in Health Regional Issues|April 3, 2026
Healthcare Resource Utilization and Costs After Disease Progression With First-Line Systemic Therapy in Patients With Advanced Endometrial Cancer in the United StatesLaura Moore-Schiltz, Solomon J Lubinga, Joseph Tkacz
Journal of Medical Economics|September 10, 2024
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspectiveSolomon J Lubinga, Lydia Walder, Mark Burton, et al.
Plos Neglected Tropical Diseases|August 12, 2016
A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African NationsDavid Watkins, Solomon J Lubinga, Bongani Mayosi, et al.
Blood Transfusion = Trasfusione Del Sangue|November 29, 2016
Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasmaJoseph B Babigumira, Solomon J Lubinga, Emma Castro, et al.
Journal of Managed Care & Specialty Pharmacy|August 23, 2023
Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitorsDavid Stenehjem, Solomon J Lubinga, Aozhou Wu, et al.
Applied Health Economics and Health Policy|May 11, 2015
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in UgandaSolomon J Lubinga, Byamah B Mutamba, Angelo Nganizi, et al.
Plos One|November 13, 2015
Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in UgandaSolomon J Lubinga, Esther C Atukunda, George Wasswa-Ssalongo, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|August 26, 2023
Cost Effectiveness of Early Endovenous Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis in the United KingdomJoseph B Babigumira, Stephen A Black, Solomon J Lubinga, et al.
Pageof 4